Daphne O. Martschenko, PhD

@daphmarts.bsky.social

🧬Assistant Professor of Biomedical Ethics @ Stanford 📕Author of WHAT WE INHERIT (2026) 🐈 Mom to Sassy & 🙋🏾‍♀️ Mom to Théa 🧘🏾‍♀️Yogi in training daphnemartschenko.com

I think this work really underscores that we are at a turning point in human genetics. There is a growing consensus that doing good research in human genetics requires an expanded skillset (including, e.g., one that can navigate the relationship between genetics, ancestry, and pop descriptors) (1/)

Jayati Sharma, PhD, ScM@jayatirsharma.bsky.social · 4w ago

In what has been a labor of love & joyful collaboration, we are super excited to share our preprint on recommendations towards the ethical and accurate use of population descriptors generated from a survey by trainees, for trainees. www.biorxiv.org/content/10.6...

-Water used at power plants that supply electricity to data centers can be greater than the amount of water used in the data centers themselves. -" $170 billion of AI data-center capacity has been blocked, stalled or canceled since 2024" www.wsj.com/tech/ai/ai-d...

AI Data Centers Use Far More Water Than Most Tech Giants Report

Water used at the power plants that supply electricity to data centers can be much greater than the water used in the data centers themselves.

wsj.com

"...readers who likely feel more attuned to one of the authors’ views at the start of the book will come to appreciate the other side as they learn more about polygenic scores, social genomics, and their influence on genetic myths." undark.org/2026/02/20/b...

Book Review: The Societal Impact of Genetic Research

In “What We Inherit,” Sam Trejo and Daphne O. Martschenko examine the link between genetic myths and social genomics.

undark.org

Lots to unpack about the 1 pivotal trial default. www.nejm.org/doi/full/10.... For now a few points: 1. FDA is not legally permitted to set policy by journal article. This must stop. 2. This is not likely to give industry much stability. FDA can decide any time that the default doesn't apply. 1/

One Pivotal Trial, the New Default Option for FDA Approval — Ending the Two-Trial Dogma | NEJM

This Sounding Board announces a new FDA policy that the default requirement for FDA approvals will be one robust pivotal trial plus confirmatory evidence, rather than two trials.

nejm.org